Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor

Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated success in the treatment of hematological malignancies; however, its efficacy and applications in solid tumors remain limited. Immunosuppressive factors, particularly inhibitory checkpoint molecules, restrict CAR T cell activity i...

Full description

Bibliographic Details
Main Authors: Jingjing Zhao, Jiebin Dong, Changwen Deng, Qianjing Zhang, Shicheng Sun, Honggang Li, Yun Bai, Hongkui Deng
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
Cancer immunotherapy
chimeric antigen receptor T
immune-checkpoint
PD1
TIGIT
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2265703

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2023.2265703

Similar Items